

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No: L24239MH1987PLC043662

Date: 12.02.2021

To

BSE Ltd.

Listing Department,

Phiroze Jeejeebhoy Towers,

Dalal Street - Fort,

Mumbai – 400 001

Ref.: BSE Scrip Code - 539730

Subject: Outcome of Board Meeting held on 12th February, 2021

Dear Sir / Madam,

1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; we wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as "the Company"), at their Meeting held on Friday, February 12, 2021; had considered and approved the Unaudited Financial Results of the Company for the Quarter and Nine months ended December 31, 2020; along with the Limited Review Report issued by M/s. Savla & Associates, Statutory Auditors of the Company; the copies of which are attached hereunder.

2. Adoption and approval of Cost Audit Report for Financial Year 2019-20.

The Meeting of the Board Commenced at 3:00 P.M. and concluded at 5:30 P.M.

Kindly take the same on your Records.

Thanking you,

For Fredun Pharmaceuticals Limited





Ankita Joshi

Company Secretary cum Compliance Officer

Membership No: ACS43193.

Encl.: A/a Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)
Phone No.: 91-22- 4031 8111 Fax : 91-22-4031 8133
Factory Address: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2020

Rs. In Lakhs

PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
	Unaudited			Unaudited		Audited
	31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
1 Income from Operations						
Net Sales /IncomeFrom Operation (Net of GST)	4509.87	3206.80	2622.93	9042.92	8587.80	11029.86
2 Other Operating Income	46.91	153.17	162.75	248.10	220.07	298.99
3 Total income from operatoins (net)	4556.78	3359.97	2785.68	9291.02	8807.87	11328.85
4 Expenses						
a) Cost of Material Consumed	3650.55	1599.89	2149.10	6333.68	6136.97	8518.42
b) Cost of Material Consumed for R & D	12.77	10.45	26.15	30.50	49.28	67.22
c) Other R & D Expenses	0.00	3.44	4.82	4.14	9.36	0.00
d) Changes in inventories of finished goods, work-in-progress and stock in trade	69.78	791.35	(143.94)	691.17	557.44	(504.27)
e) Manufacturing & Service Cost ****	117.76	129.99	82.64	296.06	323.52	528.89
f) Finance Costs	119.09	91.50	97.73	287.13	318.53	441.39
g) Emploeyss benefits expenses	212.82	232.39	186.44	619.14	551.44	894.77
h) Depreciation and amortisation expenses	52.80	49.37	47.55	148.54	140.53	187.87
i) Provision for Doubtful Debts	0.00	0.00	0.00	0.00	0.00	0.00
j) Other Expenses	187.55	252.57	233.37	544.36	507.89	945.10
Total expenses	4423.12	3160.95	2683.86	8954.72	8594.96	11079.39
5 Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	133.66	199.02	101.82	336.30	212.91	249.46
6 Exceptional items / Prior Period Item	0.00	(116.37)	0.00	(116.37)	0.00	0.00
7 Profit/(Loss) from ordinary activities before tax (5-6)	133.66	82.65	101.82	219.93	212.91	249.46
8 Tax Expenses	0.00	0.00	0.00	0.00	0.00	59.27
9 Profit/(Loss) from continuing operations	133.66	82.65	101.82	219.93	212.91	190.19
10 Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11 Tax Expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12 Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00
13 Profit/ (Loss) for the period	133.66	82.65	101.82	219.93	212.91	190.19
14 Other comprehensive Income						
A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be re-classified to profit / loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
15 Paid up Equity Share Capital (Face Value of Rs-10/- each)	398.96	398.96	398.96	398.96	398.96	398.96
16 Reserves excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	3733.16
17 Earning per Share (EPS) (before & after extra ordinary items)						
- Basic/ Diluted Earning Per Share (Rs.)	3.35	2.07	2.55	5.51	5.34	4.77
A 1) Public Shareholding						
Number of shares	1913524	1913524	1913524	1913524	1913524	1913524
Percentage of shareholding	47.96	47.96	47.96	47.96	47.96	47.96
2) Promoters and promotor group shareholding						
a) Pledged/Encumbered						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-	-	-	-	-
- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-	-	-
b) Non-encumbered						
- Number of shares	2076110	2076110	2076110	2076110	2076110	2076110
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of total share capital of the Company)	52.04	52.04	52.04	52.04	52.04	52.04

NOTES:-

1) The above results were taken on record by the Board Of Directors at the meeting held on 12.02.2021

For FREDUN PHARMACEUTICALS LTD.

DIRECTOR



Office Address:

Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Phone No.:

91-22-4031 8111 91-22-4031 8133

Factory Address:

14, 15, 16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.:

+917045957828, +917045957829, +917045957830, +917045956857

E-Mail:

business@fredungroup.com

www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No: L24239MH1987PLC043662

- 2) **** Previous year's figures have been regrouped/rearranged wherever necessary.
- 3) During the quarter ended 31st Dec 2020 there are no investor's complaints pending & no investor's complaints were received by the company during this period
- 4) Provision for deferred tax and Provision for Income Tax as applicable will be made at the end of the year
- 5) The above result have already been approve by the Audit Committee of the board
- 6) This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1st April 2017, the Company has for the first time adopted Ind AS with a transition date of 1st April 2016.

7) Employee Benefit Expense

Particular	Quarter Ended			Nine Months Ended		Year Ended
	Unaudited			Unaudited		Audited
	31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
Break – up of Employee Benefit						
Salary & Wages	180,27,225.00	203,40,503.00	174,13,882.00	526,93,206.00	514,54,012.00	701,05,314.00
Director Remuneration	12,30,000.00	12,30,000.00	12,30,000.00	36,90,000.00	36,90,000.00	49,20,000.00
Contributiomm to Provident and Other Funds	14,18,812.00	5,65,340.00	10,96,179.00	30,74,907.00	30,67,224.00	40,03,221.00
Share Base Payment to employees	0.00	0.00	0.00	0.00	0.00	0.00
Staff Welfare Expenses	6,06,141.00	5,10,472.00	7,66,366.00	23,88,429.00	11,45,149.50	21,27,555.00

8) Gain/ Loss on account of Foreign Exchange Fluctuation (Included in other Income)

Particular	Quarter Ended			Nine Months Ended		Year Ended
	Unaudited			Unaudited		Audited
	31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
Gain / Loss on Account of Foreign Exchange Fluctuation (Add in Other Income)	9,36,122.00	11,03,578.00	12,47,979.00	11,07,156.88	14,19,013.88	23,06,894.00
Loss on Account of Foreign Exchange (Record In Indirect Expenses)	0.00	0.00	0.00	0.00	0.00	0.00



For FREDUN PHARMACEUTICALS LTD.

DIRECTOR

Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Phone No.: 91-22- 4031 8111 Fax : 91-22-4031 8133

Factory Address: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

9) Reconciliation of Net Profit between Previous GAAP and IND AS

Quarter ended 31.12.2020

	I- GAAP	Effect of	IND -AS
	Figures in Lakhs	Transition to IND AS	Figures in Lakhs
Income from Operations			
Net Sales / Income From Operation (Net of GST)	4509.87	-	4509.87
Other Operating Income	46.91	-	46.91
Total income from operations (net)	4556.78	-	4556.78
Expenses			
a) Cost of Material Consumed	3650.55	-	3650.55
b) Cost of Material Consumed for R & D	12.77	-	12.77
c) Other R & D Expenses	0.00	-	0.00
d) Changes in inventories of finished goods, work-in-progress and stock in trade	69.78	-	69.78
e) Manufacturing & Service Cost	117.76	-	117.76
f) Finance Costs	119.09	-	119.09
g) Employess benefits expenses	212.82	-	212.82
h) Depreciation and amortisation expenses	52.80	-	52.80
i) Provision for Doubtful Debts	0.00	-	0.00
j) Other Expenses	187.55	-	187.55
Total Expenditure	4423.12	-	4423.12
Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	133.66	-	133.66
Exceptional items / Prior Period Item	0.00	-	0.00
Profit/(Loss) from ordinary activities before tax (5-6)	133.66	-	133.66
Tax Expenses	0.00	-	0.00
Profit/(Loss) from continuing operations	133.66	-	133.66
Profit/(Loss) from discontinued operations	0.00	-	0.00
Tax Expense of discontinued operations	0.00	-	0.00
Profit/(Loss) from discontinued operations after tax	0.00	-	0.00
Profit/ (Loss) for the period	133.66	-	133.66
Other comprehensive Income	0.00	-	0.00
Total Comprehensive Income for the period	133.66	-	133.66

PLACE: MUMBAI

DATE : 12.02.2021

FOR FREDUN PHARMACEUTICALS LIMITED



DIRECTOR
DIN : 01745348

Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Phone No.: 91-22- 4031 8111 Fax : 91-22-4031 8133

Factory Address: 14, 15, 16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No: L24239MH1987PLC043662

UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED 31.12.2020

Rs. In Lakhs

PARTICULARS	Nine Months Ended		Year Ended
	Unaudited		Audited
	31.12.2020	31.12.2019	31.03.2020
1 Income from Operations			
Net Sales /IncomeFrom Operation (Net of GST)	9042.92	8587.80	11029.86
2 Other Operating Income	248.10	220.07	298.99
3 Total income from operatoins (net)	9291.02	8807.87	11328.85
4 Expenses			
a) Cost of Material Consumed	6333.68	6136.97	8518.42
b) Cost of Material Consumed for R & D	30.50	49.28	67.22
c) Other R & D Expenses	4.14	9.36	0.00
d) Changes in inventories of finished goods, work-in-progress and stock in trade	691.17	557.44	-504.27
e) Manufacturing & Service Cost ****	296.06	323.52	528.89
f) Finance Costs	287.13	318.53	441.39
g) Employess benefits expenses	619.14	551.44	894.77
h) Depreciation and amortisation expenses	148.54	140.53	187.87
i) Provision for Doubtful Debt	0.00	0.00	0.00
j) Other Expenses	544.36	507.89	945.10
Total expenses	8954.72	8594.96	11079.39
5 Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	336.30	212.91	249.46
6 Exceptional items / Prior Period Item	-116.37	0.00	0.00
7 Profit/(Loss) from ordinary activities before tax (5-6)	219.93	212.91	249.46
8 Tax Expenses	0.00	0.00	59.27
9 Profit/(Loss) from continuing operations	219.93	212.91	190.19
10 Profit/(Loss) from discontinued operations	0.00	0.00	0.00
11 Tax Expense of discontinued operations	0.00	0.00	0.00
12 Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00
13 Profit/ (Loss) for the period	219.93	212.91	190.19
14 Other comprehensive Income			
A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit/ loss	0.00	0.00	0.00
B (i) Items that will be re-classified to profit / loss	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit/ loss	0.00	0.00	0.00
15 Paid up Equity Share Capital (Face Value of Rs-10/- each)	398.96	398.96	398.96
16 Reserves excluding Revaluation Reserves	0.00	0.00	3733.16
17 Earning per Share (EPS) (before & after extra ordinary items)			
- Basic/ Diluted Earning Per Share (Rs.)	5.51	5.34	4.77
A 1) Public Shareholding			
Number of shares	1913524	1913524	1913524
Percentage of shareholding	47.96	47.96	47.96
2) Promoters and promotor group shareholding			
a) Pledged/Encumbured			
- Number of shares	-	-	-
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-	-
- Percentage of shares (as a % of total share capital of the Company)	-	-	-
b) Non-encumbered			
- Number of shares	2076110	2076110	2076110
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	100%	100%	100%
- Percentage of shares (as a % of total share capital of the Company)	52.04	52.04	52.04

PLACE: MUMBAI

FOR FREDUN PHARMACEUTICALS LIMITED

DATE : 12.02.2021



DIRECTOR
DIN : 01745348

Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Phone No.: 91-22- 4031 8111 Fax : 91-22-4031 8133

Factory Address: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

Savla & Associates

CHARTERED ACCOUNTANTS

8/196, Guru Sevak Kutir, Station Road

Wadala (W), MUMBAI - 400 031.

PHONE : 24102526, 24112526

FAX : 24132121


LIMITED REVIEW REPORT

**TO THE BOARD OF DIRECTORS OF
FREDUN PHARMACEUTICALS LTD
26, Manoj Industries Premises,
G.D.Ambekar Marg, Wadala,
Mumbai – 400 031.**

1. We have reviewed the accompanying Statement of Unaudited standalone Financial Result of **FREDUN PHARMACEUTICALS LTD** for the Quarter ended December 31, 2020 except for the disclosures regarding 'Public Shareholding' and Promoter Group Shareholding which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Financial Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with Indian Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of 0020Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

UDIN No - 21043901AAAADG2106

FOR SAVLA & ASSOCIATES
Chartered Accountants
(Firm Registration No.109361W)


DEEPAK G. SAVLA
(Partner)
Membership No. : 043901

Place - Mumbai
Date – 12th February, 2021

